Abstract 21P
Background
CRPC patients (pts) with loss-of-function alterations in genes associated with homologous recombination (HR) can derive benefit from both PARPi and PlCh. Cross-resistance between these agents is well recognized in other tumour types and evidence of ‘reversion’ mutations in HR genes is emerging. Yet, optimal treatment sequence and data on cross-resistance in CRPC is lacking.
Methods
In this retrospective pre-planned single-centre study we describe intra-patient responses to PlCh and PARPi, assessed by the order of these HR-deficiency-targeting-agents (HRDtA; PARPi→PlCh or PlCh→PARPi). All pts were treated with both PlCh and PARPi, but agents were not necessarily given directly sequential.
Results
All 28 CRPC pts were metastatic and HR deficient, mostly due to BRCA2 inactivation (79%). Sixteen pts received PARPi→PlCh and 12 PlCh→PARPi. Pts with PlCh→PARPi had a significant shorter time to CRPC (median 10 vs. 18 months, P=0.040) and were significantly more often synchronous metastatic (92% vs. 44%, P=0.016). Progression-free survival (PFS) on the initial HRDtA was longer than the PFS on the subsequent HRDtA (median 5.3 versus 3.4 months, P=0.016). The median PFS on PARPi, given as subsequent HRDtA, was 0.9 months shorter than when administered first. For PlCh the PFS was 3.6 months shorter as subsequent HRDtA than as initial. Of the PARPi→PlCh pts, 6/16 (38%) had a >50% PSA decline to PlCh and 2/8 (25%) evaluable pts had a radiographic response to PlCh. In the PlCh→PARPi group, 6/10 (60%) evaluable pts had a >50% PSA decline to PARPi and 5/9 (56%) a radiographic response to PARPi. In total, 12/26 (46%) had a >50% PSA decline and 7/17 (41%) a radiographic response to a subsequent HRDtA. Overall survival from CRPC did not significantly differ depending on the order of HRDtA (PARPi→PlCh 45 months vs. PlCh→PARPi 33 months, hazard ratio 1.42, P=0.401).
Conclusions
This study suggests cross-resistance between PARPi and PlCh in HR deficient CRPC pts. PlCh appears to induce less cross-resistance to PARPi than vice versa. Still, >40% of the cohort is sensitive to a subsequent HRDtA. Serial assessment of (liquid) biopsies is warranted to unravel the mechanisms defining cross-resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Radboud University Medical Center, Nijmegen, The Netherlands.
Funding
Has not received any funding.
Disclosure
I.M. Van Oort: Financial Interests, Personal and Institutional, Advisory Role: Bayer, Astellas, Janssen, MSD/AstraZeneca; Financial Interests, Institutional, Research Grant: Astellas, Janssen, Bayer. J. Schalken: Financial Interests, Personal, Invited Speaker: Astellas, Bayer. N. Mehra: Financial Interests, Personal, Advisory Board: Pfizer, Roche, MSD, AstraZeneca, Astellas, JNJ; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Funding: Astellas, Pfizer; Financial Interests, Personal and Institutional, Funding: Janssen; Financial Interests, Institutional, Invited Speaker: BMS, Janssen; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Non-Financial Interests, Personal, Leadership Role, Head of the Prostate Cancer Working Group: Dutch Uro-Oncology Study Group; Non-Financial Interests, Personal, Principal Investigator, co-PI: Prospective Bladder Cancer Infrastructure (Netherlands); Non-Financial Interests, Personal, Leadership Role: Castration-resistant Prostate Cancer Registry. All other authors have declared no conflicts of interest.
Resources from the same session
63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
Presenter: Abhishek Krishna
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions
Presenter: Randa Mahran
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
Presenter: Nancy Loos
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from <italic>Daucus carota</italic> as a potential therapy for triple-negative breast cancer
Presenter: Kayode Raheem
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
Presenter: Corinne Vannier
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
Presenter: Heloise Beutier
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
Presenter: Sofija Jovanović Stojanov
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
Presenter: Edoardo Crimini
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - MDM alterations in patients with advanced or metastatic cancers
Presenter: Iwona Lugowska
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Automated detection of typical and atypical mitotic figures for improving survival prediction in breast cancer
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract